Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Fixed-dose combinations of long-acting β2-agonist (LABA) and muscarinic antagonist (LAMA) offered superior efficacy and comparable safety to LAMA or LABA/inhaled corticosteroid (ICS), the two most commonly prescribed first-line treatments for stable moderate-to-very-severe chronic obstructive pulmonary disease (COPD), according to a meta-analysis.
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.